Latest Breaking News On - Poster release - Page 4 : comparemela.com

Message : Required fields AFM24 preclinical in vivo data will be presented as a poster Data on AFM13 in combination with adoptive NK cells will be presented during a Major Symposium Heidelberg, Germany, March 10, 2021 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that preclinical anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) ) AFM24 have been accepted for e-poster presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, being held on April 10-15. In addition, early data from a Phase 1 study evaluating AFM13 preloaded

United statesNew yorkBaden wubergCassandra choe juliakAffimednv affimedGabriele hintzenJens pahlSheena pintoTorsten hanekeUwe reuschAndreas harstrickKaty rezvaniJoachim kochArndt schotteliusMary beth sandinChristian breunig